Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours

BACKGROUND: This Phase 1 study assessed the safety and efficacy of the Porcupine inhibitor, WNT974, in patients with advanced solid tumours. METHODS: Patients (n = 94) received oral WNT974 at doses of 5–30 mg once-daily, plus additional dosing schedules. RESULTS: The maximum tolerated dose was not e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Rodon, Jordi, Argilés, Guillem, Connolly, Roisin M., Vaishampayan, Ulka, de Jonge, Maja, Garralda, Elena, Giannakis, Marios, Smith, David C., Dobson, Jason R., McLaughlin, Margaret E., Seroutou, Abdelkader, Ji, Yan, Morawiak, Jennifer, Moody, Susan E., Janku, Filip
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8257624/
https://ncbi.nlm.nih.gov/pubmed/33941878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-021-01389-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados